Loading...
XNASZVSA
Market cap2mUSD
Dec 24, Last price  
1.15USD
1D
-1.71%
1Q
-48.43%
IPO
-99.96%
Name

Zyversa Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ZVSA chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-98m
L-87.05%
-13,199,616-8,905,527-759,097,607-98,297,946
CFO
-9m
L+483.47%
-5,109,833-5,076,089-1,494,641-8,720,819

Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
IPO date
Dec 21, 2021
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
14,421
13,023
7,715
Unusual Expense (Income)
NOPBT
(14,421)
(13,023)
(7,715)
NOPBT Margin
Operating Taxes
(9,456)
745,050
821
Tax Rate
NOPAT
(4,965)
(758,073)
(8,536)
Net income
(98,298)
-87.05%
(759,098)
8,423.89%
(8,906)
-32.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,411
1,865
BB yield
-844.58%
-1.31%
Debt
Debt current
9
109
9,152
Long-term debt
9
109
Deferred revenue
Other long-term liabilities
Net debt
(3,120)
(5,685)
8,823
Cash flow
Cash from operating activities
(8,721)
(1,495)
(5,076)
CAPEX
(1)
Cash from investing activities
Cash from financing activities
5,956
5,230
FCF
17
(759,873)
(9,950)
Balance
Cash
3,138
5,902
329
Long term investments
Excess cash
3,138
5,902
329
Stockholders' equity
(103,219)
(4,920)
(52,897)
Invested Capital
114,302
104,917
49,548
ROIC
ROCE
230.39%
EV
Common stock shares outstanding
98
259
466
Price
9.00
-98.36%
549.50
 
Market cap
878
-99.38%
142,586
 
EV
(2,243)
136,901
EBITDA
(14,410)
(13,014)
(7,704)
EV/EBITDA
0.16
Interest
457
428
821
Interest/NOPBT